Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 5Melanoma 2Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Moderate Hepatic Impairment 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Meningioma 1Lymphoma 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Leukemia 1Healthy Participants 1Endometrial Neoplasms 1Disease Progression 1Chondrosarcoma 1CCCA Assessed by Ki67 Drop Below <2.7% From Baseline 1

Interventions

capivasertib 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × CCCA Assessed by Ki67 Drop Below <2.7% From Baseline × capivasertib × Clear all
NCT06607757 2025-04-02

Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer

GBG Forschungs GmbH

Phase 2 Recruiting
120 enrolled

CCCA Assessed by Ki67 Drop Below <2.7% From Baseline

Data powered by HemOnc (CC BY 4.0) Colophon âš¡